Browse our wide selection of products for your research needs
We can offer a discount on bulk orders.
Please contact our sales team for further inquiry.
| Product Name | LNP@Azoramide, lipid nanoparticles encapsulating Azoramide |
| Catalog Number | R-CW-LA001 |
| Alias | Liposome-encapsulated Azoramide |
| Appearance | Dispersion |
| Molecular Formula | N/A |
| Solubility | Dispersed in water or PBS buffer |
| Storage | 2-8°C, protected from light |
| Purity | 95%+ |
| Shelf Life | 1 year |
| Shipping Condition | low temperature transport |
| Application | Preparation of liposomes |
| Specification | 10mg:Inquiry 20mg:Inquiry 50mg:Inquiry |
| Description | LNP@Azoramide is a drug delivery system that encapsulates azoramide inside lipid nanoparticles (LNP). Lipid nanoparticles have advantages as delivery vehicles. It is mainly composed of ionizable cationic phospholipids, cholesterol, auxiliary phospholipids and polyethylene glycol-modified phospholipids. Under physiological pH conditions, ionizable cationic phospholipids are neutral. When placed in an acidic environment such as endosomes, they are protonated and positively charged, and can tightly combine with negatively charged azolamide through electrostatic interaction to achieve efficient encapsulation. Cholesterol enhances membrane fusibility, which helps LNP@Azoramide to escape from endosomes and enter the cytoplasm after it is taken up by cells. Auxiliary phospholipids stabilize the phospholipid bilayer structure and stabilize the LNP morphology. Polyethylene glycol-modified phospholipids are located on the surface of LNPs to prevent particles from aggregating, prolonging their circulation time in the body, and avoiding rapid clearance by the immune system. As an active pharmaceutical ingredient, azolamide has specific pharmacological activity. After combining with LNP, it not only improves its stability, but also improves the drug delivery efficiency, allowing azolamide to reach the site of action more accurately and exert its treatment effect. |